Get informed when a big investor buys or sells
+ FollowOvervalued by 101.4% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $79.30 Million |
|---|---|
| Enterprise Value | $78.56 Million |
| Earnings per Share | $-0.34 |
| Beta | 0.73 |
| Outstanding Shares | 75,526,900 |
| P/E Ratio | -3.29 |
|---|---|
| PEG | -13.95 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 78561.25 |
| Enterprise Value to EBIT | -5.17 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
No data
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 87.84% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Holdings and activity of institutional investors.
| Ownership % | 5.71%▼ 25.89% |
|---|---|
| Total Invested | $5.00M▼ 79.67% |
| Investors Holding | 4▼ 51.00% |
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (kno...